P rescription opioids remain commonly prescribed for pain among people living with HIV (PLWH) and those who are uninfected. 1, 2 However, accumulating evidence suggests that prescribed opioids increase the risk of infections, including community-acquired pneumonia (CAP). [3] [4] [5] [6] Some opioids impair innate and adaptive immune system defenses to bacterial infections, 7,8 suppress cough and respirations, and inhibit bronchial mucus secretion and alveolar neutrophil response to Streptococcus pneumoniae. 9,10 These findings support biological plausibility for an adverse effect of opioids on CAP risk. In addition, opioids vary in their immunosuppressive properties; for example, morphine sulfate appears to be immunosuppressive, whereas oxycodone hydrochloride does not. 3, 11 People living with HIV are more commonly prescribed opioids than uninfected comparators despite an increased risk for infectious complications in general and for CAP in particular. 2, 12 Notably, CAP is a major contributor to morbidity and mortality even in the current HIV treatment era and especially as patients age.
12 Few studies have examined the extent to which prescribed opioids affect CAP risk, and none have focused on PLWH. [3] [4] [5] 13 Prior studies have been limited to specific populations 3, 5 and relied on diagnoses and surrogate measures of frailty to adjust for disease severity. 5 Thus, using a national sample of PLWH and people without HIV and accounting for overall severity of illness with a validated measure, we conducted the present study to (1) determine the association between prescribed opioids and CAP risk and to examine whether this association differs by (2) prescribed opioid properties, including duration of opioid exposure, average (ie, mean) morphine equivalent daily dose (MEDD), and immunosuppressive properties of prescribed opioids or (3) HIV status. We hypothesized that prescribed opioids would increase CAP risk, with increasing risk at higher doses and with known immunosuppressive properties, and that associations would be stronger among PLWH compared with an uninfected comparison group.
Methods

Study Design and Data Sources
We conducted a nested case-control study using January 1, 2000, through December 31, 2012, data from the Veterans Aging Cohort Study (VACS). VACS, a prospective study of all PLWH receiving care at Veterans Health Administration (VA) medical centers across the United States and an uninfected comparison group, investigates the effect of comorbid disease on outcomes in HIV infection. 14 VACS uses data from the VA-based electronic medical record, including demographic data, medical diagnoses (based on International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes), laboratory results, and pharmacy records. We additionally linked this VA data with the Center for Medicare & Medicaid Services (CMS) data to capture CAP events outside the VA. The study was approved by the Human Investigations Committee at Yale University, New Haven, Connecticut, and the VA Connecticut Healthcare System, West Haven, and was granted a waiver of informed consent. Patients were not reimbursed for participation. The time frame during which prescribed opioids would exert an immunosuppressive effect is not known. Therefore, we chose a nested case-control design. This design allowed us to consider factors associated with CAP risk proximal and distal to the event, including proximal exposure to prescribed opioids.
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Baseline Cohort
Among VACS participants, we established a base cohort of patients who were alive as of January 1, 2000, and had a subsequent VA visit ( Figure 1 and Figure 2 ). Patients were eligible for cohort entry on receipt of their first VA outpatient nonantiretroviral (non-ARV) prescription (to ensure they received medications from the VA); the next 365 days constituted the baseline period. The baseline period was used to establish preexisting opioid use and other exclusions. Follow-up began at the end of the baseline period. To increase clinical relevance and internal validity, we excluded patients who (1) died during the baseline period, had a questionable date of death, or whose only subsequent record was a death date (n = 2150); (2) started follow-up after September 30, 2012 (n = 3596); (3) received more than 14 days of prescribed opioids during the baseline period (n = 15 530) to ensure that we captured patients who were newly prescribed opioids 16, 17 ; (4) had an initial VA opioid dosage greater than 100 mg MEDD (n = 849) to exclude patients likely prescribed opioids before transferring into the VA; (5) had a VACS Index score greater than 100 (n = 166) during the baseline period; (6) received chemotherapy or immunosuppressive medications other than systemic or inhaled corticosteroids (n = 5524) 18 because this factor may increase CAP risk; or (7) had missing data (n = 2922). VACS Index is a validated measure of morbidity and mortality in patients with and without HIV that is calculated based on HIV biomarkers (CD4 cell count and HIV viral load, where values are assumed to be normal for uninfected patients), hemoglobin level, Fibrosis 4 Index for Liver Fibrosis score, estimated glomerular filtration rate, and hepatitis C status. 19 Scores greater than 100 indicate a 20% risk of death in the next year, a proxy for severe illness.
Selection of Cases and Controls
We next identified cases and controls. Using VA and CMS data, we identified patients with CAP requiring hospitalization (ie, cases). Incident CAP was defined using ICD-9 codes 480 to 
Measures of Prescribed Opioid Exposure
The primary exposure of interest was prescribed opioid use in the 365 days before the index date determined using outpatient VA pharmacy fill and refill data. We determined receipt of oral and transdermal opioids for pain (ie, excluding buprenorphine hydrochloride and methadone hydrochloride for opioid use disorder). 18, 22 We characterized prescribed opioid exposure based on the timing of the prescription, dose, and immunosuppressive properties to create a composite variable ( Table 1) .
Covariates
We selected covariates that may confound the association between prescribed opioids and CAP risk. [3] [4] [5] 25 Sociodemographic characteristics included age, sex, and race/ethnicity. All other covariates were defined based on data collected between the date of initial non-ARV prescription to 30 days before the index date. We used laboratory values closest to the end of this window. Diagnoses were considered present if assigned before the end of this window. Clinical characteristics, determined based on the presence of 1 inpatient or 2 outpatient ICD-9-CM codes, included HIV, hepatitis C (with positive antibody or detectable RNA), diabetes mellitus (including laboratory results and medications), chronic obstructive pulmonary disease, congestive heart failure, stroke, pain-related diagnoses, alcohol-and other drug-related diagnoses, and prior CAP. Pain-related diagnoses were classified as previously described. acteristics of the 4246 CAP cases with those of the 21 146 controls in our sample. We also compared cases and controls by HIV status. We ran bivariable and multivariable conditional (to account for matching of cases and controls) logistic regression to estimate unadjusted and adjusted odds ratios (ORs) and 95% CIs for CAP risk associated with opioid exposure characterized with a composite variable that captured (1) prescribed opioid timing, (2) average MEDD, and (3) receipt of an immunosuppressive opioid (yes vs unknown or no). We also ran models stratified by HIV status and formally checked for an interaction between prescribed opioid characteristics and HIV status. In sensitivity analyses, we censored patients with a cancer diagnosis (excluding skin cancers except melanoma), those who achieved a VACS Index score greater than 100 during follow-up, or those who had a diagnosis of an opioid use disorder (based on ICD-9 code for opioid abuse or dependence).
In post hoc analyses, we used a 3-level variable to assess the effects of immunosuppressive opioids (yes, unknown, or no) on CAP risk. We considered statistical significance to be a 2-sided P < .05. Analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc).
Results
Patient Demographic and Clinical Characteristics
Cases and controls totaled 25 392 participants (98.9% male and 1.1% female; mean [SD] age, 55 [10] years). Baseline characteristics of cases and controls are presented in Table 2 .
Prescribed Opioid Characteristics
In the year before the index date, cases were more likely than con- b If a patient only had prescribed opioids during 0 to 4 days before the index date, this was not considered as opioid exposure and was not included in above calculations to decrease risk of indication bias. 24 In cases, this duration of prescription could be for treatment of CAP symptoms.
c Dose categories defined based on the distribution in study sample. 
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Prescribed Opioid Characteristics by HIV Status
In adjusted analyses stratified by HIV status, CAP risk tended to be greater among PLWH with current prescribed opioids, especially immunosuppressive opioids, compared with uninfected patients ( Figure 3 and eTable 2 in the Supplement). For example, among PLWH, compared with no prescribed opioids, the OR of CAP was 3.26 (95% CI, 2.24-4.73) higher with current high-dose immunosuppressive opioids; among uninfected patients, the OR of CAP was 3.13 (95% CI, 2.14-4.57). For current medium-dose immunosuppressive opioids, the OR of CAP was 2.33 (95% CI, 1.60-3.40) for PLWH vs 1.76 (95% CI, 1.20-2.57) for uninfected patients. The overall interaction term for opioid × HIV status, however, was not significant (P = .36).
Sensitivity and Post Hoc Analyses
In sensitivity analyses that excluded patients with a cancer diagnosis (n = 1561), those with a VACS Index score greater than 100 during follow-up (n = 92), or those with an opioid use disorder (n = 1690), results were not substantively different. In post hoc analyses in the overall sample, compared with no prescribed opioids and within each stratum, prescribed opioids with unknown immunosuppressive properties appeared to be associated with lower odds of CAP compared with opioids with immunosuppressive properties or no immunosuppressive properties.
Discussion
In this large, national cohort of patients with detailed prescribed opioid exposure, we found a strong, independent association between prescribed opioids and the risk of CAP requiring hospitalization in PLWH and uninfected patients. This finding was true for current and past-year prescribed opioid receipt. In addition, among those prescribed opioids, we found that the CAP risk increased with a higher current opioid dose and in patients prescribed opioids with known immunosuppressive properties. Notably, PLWH appear to have a greater CAP risk at lower opioid doses and particularly with immunosuppressive opioids compared with uninfected patients. No previous research has compared the association of prescribed opioids with CAP risk among those with and without HIV infection. [3] [4] [5] 13 Our findings complement and extend the literature indicating that prescribed opioids have clinically relevant immunosuppressive effects. Three prior studies are most relevant. [3] [4] [5] Inacohort of community-dwelling older adults (1039 cases and 2022 controls), 3 CAP risk was greatest immediately after initiation of prescribed opioid treatment, and immunosuppressive opioids were associated with increased risk. That study did not find that past prescribed opioids or average MEDD among those with longterm prescribed opioids were associated with CAP risk. Similarly, in a self-controlled case series of patients with rheumatoid arthritis, 4 an adjusted incidence rate ratio of 1.39 (95% CI, 1.19-1.62) was found for serious infections requiring hospitalization. However, although that study found an incidence rate ratio of 1.22 for CAP during periods of prescribed opioids compared with those without, the 95% CI crossed 1.00 (0.99-1.51). 4 Finally, in a nested case-control study including 1233 cases with invasive pneumococcal disease, including pneumonia, and 24 399 controls, 5 investigators found that cases had greater odds than controls of prescribed opioid use with an AOR of 1.62 (95% CI, 1.36-1.92). These associations were strongest for prescribed opioids that were long acting, high potency, and high dose. As in these studies, [3] [4] [5] we found that current receipt of prescribed opioids and higher doses were associated with greatest CAP risk. Our finding that past prescribed opioid receipt was also associated with CAP risk may be associated with prolonged immunosup- Includes 25 392 cases and controls. Multivariable conditional logistic regression models were stratified by HIV status and adjusted for smoking status, diabetes mellitus, chronic obstructive pulmonary disease, congestive heart failure, stroke, alcohol-and other drug-related diagnoses, prior pneumonia, long-term benzodiazepine receipt, prescribed oral and inhaled corticosteroid receipt, influenza vaccination, pneumococcal vaccination, and Veterans Aging Cohort Study Index score. P = .36 for interaction of immunosuppressive properties × HIV status from unstratified model. Error bars indicate 95% CI. AOR indicates adjusted odds ratio; CAP, community-acquired pneumonia; MEDD, morphine equivalent daily dose; and PLWH, people living with HIV.
a Current indicates prescribed opioid receipt 5 to 60 days before the index date; past, 61 to 365 days before the index date.
pressive effects, stockpiling unused medication, which may enable use of medications longer than prescribed, and/or unmeasured or residual confounding. Consistent with preclinical studies demonstrating differential immunosuppressive effects of specific opioids, 11 we observed that CAP risk was greatest with use of immunosuppressive prescribed opioids, including codeine, dihydrocodeine bitartrate, fentanyl, and morphine. Notably, prior work 3, 5 has found that receipt of long-acting opioids is associated with increased CAP risk. This finding is consistent with ours given that morphine, the most commonly prescribed long-acting opioid in our data, is considered immunosuppressive, and use of long-acting formulations is correlated with receipt of higherdose opioids.
We observed a differential association of prescribed opioids with CAP risk by HIV status based on opioid dose and immunosuppressive properties as the magnitude of the association between these opioid characteristics, and CAP risk was higher for PLWH compared with uninfected patients. We have reported that prescribed opioids are not associated with CD4 cell count recovery among patients initiating ARV therapy.
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The findings from the present study, however, suggest that HIV infection may make patients more susceptible to the effects of prescribed opioids and are consistent with our findings demonstrating that PLWH have a greater mortality risk at lower opioid doses than uninfected individuals.
28 Consistent with our hypothesis, our findings suggest that PLWH may be more susceptible to the effects of immunosuppressive medications and with lower levels of exposure.
Strengths and Limitations
Several strengths of our study deserve mention. First, by excluding patients who received more than 14 days of prescribed opioids during the baseline period, we restricted our sample to individuals who were relatively naive to prescribed opioids to decrease bias. 16 Second, we had comprehensive ascertainment of CAP by including data from the VA and CMS and applied validated methods. 21 Third, we used a validated measure of morbidity and mortality to account for underlying disease severity and to minimize confounding. 19 Fourth, we accounted for other potential confounders in the association between prescribed opioids and CAP risk, including comorbid conditions, such as alcohol use disorder; use of immunosuppressive medications; and preventive care. However, residual confounding may still exist. For example, we adjusted for smoking status but not for the number of cigarettes or pack-years of smoking history for our patients. Fifth, more than 95% of cases and controls had a VA or CMS visit in the 18 months before the index date, indicating that our data comprehensively captured diagnoses and health care services for participants in our sample. Finally, our large sample size allowed us to increase precision of the estimated association of prescribed opioids with CAP risk. Our study also has limitations. First, although we were able to adjust for confounders proximal to the CAP event, we cannot completely rule out unmeasured confounding. Second, we assumed that patients took opioid medications as prescribed and were unable to account for opioids prescribed outside the VA. However, most VA patients predominantly use VA pharmacies.
14,29 Third, we were unable to account for nonmedical use of prescribed opioids; however, a previous study 30 
Conclusions
This study adds to growing evidence of potential medical harms associated with prescribed opioids. Health care professionals should be aware of this additional CAP risk when they prescribe opioids, and future studies should investigate the effects of opioids prescribed for longer durations and on other immune-related outcomes. Understanding whether mitigating the risk of prescribed opioids for CAP is possible by using a lower dose and nonimmunosuppressive opioids awaits further study. 
